Request Demo
Last update 24 Sep 2026
SCTB-35
Last update 24 Sep 2026
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms SCTB35 |
Target |
Action inhibitors |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
5
Clinical Trials associated with SCTB-35NCT07819188
A Phase Ib/II Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of SCTB35 in Combination With SCTB41, With or Without Concomitant Chemotherapy, in Patients With Non-Hodgkin's Lymphoma.
NCT07562022
A Phase 3 Randomized, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide Versus Rituximab and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
NCT07570823
A Phase 3 Randomized, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
100 Clinical Results associated with SCTB-35
Login to view more data
100 Translational Medicine associated with SCTB-35
Login to view more data
100 Patents (Medical) associated with SCTB-35
Login to view more data
100 Deals associated with SCTB-35
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Follicular Lymphoma | Phase 3 | China | 09 Jun 2026 | |
| Refractory Follicular Lymphoma | Phase 3 | China | 09 Jun 2026 | |
| Diffuse large B-cell lymphoma recurrent | Phase 3 | China | 04 Jun 2026 | |
| Primary cutaneous diffuse large cell B-cell lymphoma | Phase 3 | China | 04 Jun 2026 | |
| Systemic Lupus Erythematosus | Phase 2 | China | 17 Jan 2025 | |
| CD20 Positive B-Cell Non-Hodgkin Lymphoma | Phase 1 | China | 09 Apr 2024 | |
| CD20 positive B-Cell Lymphoma | Phase 1 | China | 01 Apr 2024 | |
| Diffuse large B-cell lymphoma refractory | IND Approval | China | 29 Apr 2026 | |
| Recurrent Follicular Lymphoma | IND Approval | China | 16 Apr 2026 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free